Sars Test Results

Human IgG Quick test strip

E411A02-10 10 tests
EUR 150

Human IgG antibody Laboratories manufactures the sars test results reagents distributed by Genprice. The Sars Test Results reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Sars products are available in stock. Specificity: Sars Category: Test Group: Results

Mouse IgG Quick test strip

10 tests
EUR 150

Dengue IgG/IgM Rapid Test

1 kit Ask for price

True Blue

5.0mg
EUR 595

True Blue

10mg Ask for price
Description: True Blue

True Blue

1g Ask for price
Description: True Blue

True Blue

1mg Ask for price
Description: True Blue

True Blue

50mg Ask for price
Description: True Blue

Results information

TruStrip RDT Cow/Bovine Infectious rhinitis (IBR) antibody rapid test card, results is 2-10 mins, 50 cards/pk

RV-500300-RDT 1 pk Ask for price

TruStrip RDT Canine distemper virus (hardpad disease) antigen rapid test card, results is 2-10 mins, 50 cards/pk

RV-501200-RDT 1 pk Ask for price

TruStrip RDT Humanized Ebola IgG (humanized IgGs expressed in tobacco or other plants) rapid test (results in 2-10 min), 25 cassettes/pk

AE-320880-RDT-25 1 pk
EUR 351.6

TruStrip RDT Human Anti-Zaire Ebola virus glycoprotein (GP) antibody rapid test (visual results in 2-10 min), 10 cassettes/pk

AE-320625-RDT 1 pk
EUR 351.6

Multiple organs tumor tissue array, including pathology grade, TNM, clinical stage IHC markers (ER, PR, Her-2) results, 118 cases/208 cores

BR20838 row: 13; column: 16; cores: 208; cases: 118
EUR 474
Description: Multiple organs tumor tissue microarray, containing 80 cases of breast invasive carcinoma of no special type, 10 cancer adjacent breast tissue, duplicate cores per case, 4 ovary serous adenocarcinoma, 4 uterus endometrioid adenocarcinoma, 6 rectum adenocarcinoma, 6 colon adenocarcinoma, 2 esophagus squamous cell carcinoma, 2 stomach carcinoma, 2 pancreas adenocarcinoma, 2 lung carcinoma, single core per case

Breast tumor tissue array (18 of 25), including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2) results,104 cases/208 cores

BR20824 row: 13; column: 16; cores: 208; cases: 104
EUR 474
Description: Breast tumor tissue microarray (slide 18 of 2600 cases of breast cancer survey slide set), containing 83 cases of invasive carcinoma of no special type, 4 mucinous carcinoma, 9 medullary carcinoma, 6 invasive lobular carcinoma, 1 each of apocrine carcinoma and cystosarcoma phyllodes, duplicate cores per case

Breast cancer tissue array with normal breast tissue, including pathology grade, TNM, clinical stage and Her-2 results, 5 cases/5 cores

BRC051 row: 1; column: 5; cores: 5; cases: 5
EUR 42
Description: Breast invasive carcinoma of no special type microarray, containing 4 casee of breast invasive carcinoma of no special type and 1 normal breast tissue, single core per case

anti- SARS antibody

FNab07609 100µg
EUR 658.5
Description: Antibody raised against SARS

SARS-CoV-2 Antigen Rapid Test

INCP-502H 25 Tests
EUR 8.75

SARS-CoV-2 Antigen Rapid Test Kit

CoV2Ag-1 1T
EUR 9.6
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again.

SARS-CoV-2 Antigen Rapid Test Kit

CoV2Ag-25 25T/kit
EUR 42
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection.

Breast invasive carcinoma of no special type tissue array, including pathology grade, TNM, clinical stage and IHC markers (PR, Ki-67, Her-2) results, 10 cases/10 cores

FMG010 row: 3; column: 4; cores: 10; cases: 10
EUR 78
Description: Breast invasive carcinoma of no special type tissue microarray, containing 10 cases of breast invasive carcinoma of no special type, single cores per case

SARS-CoV-2 Rapid Antigen Test Nasal

9901-NCOV-03G 25 Tests/Kit
EUR 112.8
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

Breast cancer tissue array (most of triple negative), including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2) results, 60 cases/120 cores, replacing BR1201a

BR1201b row: 10; column: 12; cores: 120; cases: 60
EUR 354
Description: Breast carcinoma tissue microarray (most of triple negative), containing 56 cases invasive carcinoma of no special type, 2 cases invasive papillary adenocarcinoma, 1 each of medullary carcinoma and apocrine carcinoma, duplicate core per case

Breast cancer tissue array (most of Her-2 subtype), including molecular typing, pathology grade, TNM and clinical stage, with IHC results of ER, PR and Her-2, 50 cases/150 cores

BR1510 row: 10; column: 15; cores: 150; cases: 50
EUR 354
Description: Breast carcinoma tissue microarray, containing 45 cases of invasive carcinoma of no special type, 2 medullary carcinoma, 1 each of metaplastic carcinoma, mixed carcinoma and apocrine carcinoma, triplicate cores per case

Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR, Her2, Ki-67) results, 72 cases/72 cores, replacing BC08013d

FMG08013e row: 8; column: 9; cores: 72; cases: 72
EUR 168
Description: Breast carcinoma with adjacent normal breast tissue microarray, containing 63 cases of invasive carcinoma of no special type, 6 medullary carcinoma, 3 adjacent normal breast tissue, single core per case

Accu-Tell COVID-19 IgG/IgM Rapid Test

GEN-B352-20tests 20 tests
EUR 283.2
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.